Clinical trials: Conjunctiva; Disorder
Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
Ocular mucous membrane pemphigoid (MMP) is an autoimmune, scarring conjunctivitis that can lead to vision loss and permanent disability. It is a rare disorder with an estimated incidence of 1 in 60,000.
- Trial name
- NCT05263505
- Testing
- Baricitinib 2 MG [Olumiant], Methotrexate, Azathioprine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Washington University School of Medicine
Bacterial Infections, Eye Infections
Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers
The purpose of this study is to evaluate the drug concentrations of AzaSite™ compared to Vigamox at various time points in conjunctiva tissue of healthy volunteers
- Trial name
- NCT00564447
- Testing
- Azithromycin, Moxifloxacin
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Allergic Conjunctivitis
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis
- Trial name
- NCT03494504
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- 7 sites in United States
- Volunteers
- 318 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Allergic Conjunctivitis
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01881113
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aciex Therapeutics, Inc.
Rhinitis, Allergic, Conjunctivitis
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641/Amb a 1-U) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period.
- Trial name
- NCT00770315
- Testing
- Ambrosia artemisiifolia allergen extract (Amb a 1-U)
- Volunteers
- 784 people
- Sponsor
- ALK-Abelló A/S
Bacterial Conjunctivitis
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
- Trial name
- NCT00518089
- Testing
- Gatifloxacin 0.5% eye drops
- Where
- 2 sites in United States, India
- Volunteers
- 859 people
- Sponsor
- Allergan
Conjunctivitis, Conjunctivitis, Bacterial
Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects
Phase I clinical trial, to evaluate the safety and tolerability of the ophthalmic solution PRO-174 versus Sophixín Ofteno®, elaborated by Laboratorios Sophia, S.A. of C.V.
- Trial name
- PRO-174/I (NCT03519516)
- Testing
- PRO-174, Sophixín Ofteno®
- Where
- Mexico
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal
Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
Topical rVA576 for treatment of atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC),and severe allergic conjunctivitis (seasonal (SAC) or perennial (PAC)): a randomised placebo-controlled double masked parallel…
- Conditions
- Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal, Conjunctivitis, Allergic
- Trial name
- NCT04037891
- Testing
- rVA576
- Where
- 9 sites in Spain, United Kingdom
- Volunteers
- 12 people
- Sponsor
- AKARI Therapeutics
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Pterygium, Ocular Pain
Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.
Title of the study Efficacy and safety of PRO-155 (Zebesten ofteno®) on inflammation of the conjunctival surface in subjects with grade I-III pterygium vs placebo. Hypothesis H0.
- Conditions
- Pterygium, Ocular Pain, Ocular Inflammation, Post-surgical Inflammation
- Trial name
- PRO-155/IV (NCT03521791)
- Testing
- PRO-155
- Where
- 3 sites in Mexico
- Volunteers
- 166 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator
In this study, the safety and effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator after 180 days of use in participants with aqueous tear deficiency will be evaluated.
- Trial name
- NCT02526290
- Testing
- Intranasal Lacrimal Neurostimulator (Oculeve)
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- Oculeve, Inc.
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease.
- Trial name
- NCT05586152
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Invirsa, Inc.